EuroPCR 2021: Findings From the POEM Study

Подробнее о видео

Dr Giulio Stefanini (Humanitas Research Hospital, Milan, IT) discusses the findings from the multicentre POEM trial.

The trial assessed the safety of the bioresorbable polymer-coated everolimus-eluting Synergy® stent in CAD patients undergoing PCI, followed by 1-month dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR).

Questions:
1. What is the POEM Study and what does it aim to address?
2. Describe the design, patient population and endpoints?
3. What are the key findings?
4. What conclusions can be made and what are the implications on practice?
5. What are the next steps?

Recorded remotely from Milan, 2021.